Rituximab plus Peg-interferon- /ribavirin compared with Peg-interferon- /ribavirin in hepatitis C–related mixed cryoglobulinemia
نویسندگان
چکیده
1Department of Internal Medicine, Assistance Publique–Hopitaux de Paris, Groupe Hospitalier Pitié-Salpétrière, Paris; 2Université Pierre et Marie Curie, Paris VI, Centre National de la Recherche Scientifique Unite Mixte de Recherche 7087, Groupe Hospitalier Pitié-Salpétrière Paris; 3Department of Biostatistics, Hôpital Saint-Louis, Paris; 4Department of Nephrology, Hôpital Européen George Pompidou, Paris; 5Department of Internal Medicine, Hôpital Edouard Herriot, Lyon; 6Department of Internal Medicine, Hôpital Lapeyronie, Montpellier; and 7Department of Immunobiology, Groupe Hospitalier Pitié-Salpétrière, Paris, France
منابع مشابه
Pegylated interferon- , ribavirin, and rituximab combined therapy of hepatitis C virus–related mixed cryoglobulinemia: a long-term study
This study illustrates the use and efficacy of a combination of pegylated interferon(Peg-IFN) and ribavirin (RBV), with or without rituximab (RTX), in hepatitis C virus (HCV)–related mixed cryoglobulinemia (MC). Twenty-two patients with HCVrelated MC received Peg-IFN(2a: 180 g or 2b: 1.5 g/kg) weekly plus RBV (1000 or 1200 mg) daily for 48 weeks, and RTX (375 mg/m2) once a week for 1 month foll...
متن کاملPegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study.
This study illustrates the use and efficacy of a combination of pegylated interferon-alpha (Peg-IFN-alpha) and ribavirin (RBV), with or without rituximab (RTX), in hepatitis C virus (HCV)-related mixed cryoglobulinemia (MC). Twenty-two patients with HCV-related MC received Peg-IFN-alpha (2a: 180 mug or 2b: 1.5 mug/kg) weekly plus RBV (1000 or 1200 mg) daily for 48 weeks, and RTX (375 mg/m(2)) o...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Pegylated interferon- , ribavirin, and rituximab combined therapy of hepatitis C virus–related mixed cryoglobulinemia: a long-term study
This study illustrates the use and efficacy of a combination of pegylated interferon(Peg-IFN) and ribavirin (RBV), with or without rituximab (RTX), in hepatitis C virus (HCV)–related mixed cryoglobulinemia (MC). Twenty-two patients with HCVrelated MC received Peg-IFN(2a: 180 g or 2b: 1.5 g/kg) weekly plus RBV (1000 or 1200 mg) daily for 48 weeks, and RTX (375 mg/m2) once a week for 1 month foll...
متن کاملCombined Treatment with Antiviral Therapy and Rituximab in Patients with Mixed Cryoglobulinemia: Review of the Literature and Report of a Case Using Direct Antiviral Agents-Based Antihepatitis C Virus Therapy
Mixed cryoglobulinemia (MC) is an autoimmune/B-cell lymphoproliferative disorder associated with Hepatitis C Virus (HCV) infection, manifesting as a systemic vasculitis. In the last decade, antiviral treatment (AT) with pegylated interferon (Peg-IFN) plus ribavirin (RBV) was considered the first therapeutic option for HCV-MC. In MC patients ineligible or not responsive to antivirals, the anti-C...
متن کاملEXTENDED REPORT Peg-IFNα/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24
To cite: Saadoun D, Resche Rigon M, Thibault V, et al. Ann Rheum Dis Published Online First: [please include Day Month Year] doi:10.1136/annrheumdis2012-202770 ABSTRACT Background The standard-of-care treatment of patients with hepatitis C virus (HCV)-mixed cryoglobulinemia (MC) vasculitis includes pegylated interferon α (PegIFN)-α plus ribavirin and/or rituximab. About 30–40% of patients are n...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2010